Group 1 pulmonary hypertension (or pulmonary arterial hypertension) is a rare, highly complex, and progressive disorder that is incurable and ultimately can lead to premature death. PAH causes ...

Because PAH is progressive, ongoing risk assessment is an essential part of PAH management. Once diagnosed, the overall treatment goal for people with PAH is to achieve and maintain a low-risk status ...

At Janssen, our mission is to put the needs and well-being of the people we serve as a top priority. As part of the larger healthcare ecosystem, we also recognize our responsibility to listen to and ...

COPD diagnosis Researchers have proposed that the COPD Assessment Test (CAT) be used as a US Food and Drug Administration (FDA) clinical outcomes assessment tool. Members of the COPD Biomarker ...

AHA scientific statement provides a framework for standardizing baseline and provocative invasive hemodynamic protocols in HF ...

Experience with terlipressin (TP) in the neonatal field is scarce. We describe the effects of TP on pulmonary circulation, studied with echocardiography, in an asphyxiated septic cooled infant with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The REVEAL Lite 2 risk assessment tool is prognostic of ...

myCOPD can be used in the NHS while more evidence is generated, to deliver pulmonary rehabilitation programmes for adults with chronic obstructive pulmonary disease (COPD) who cannot have or do not ...

Pulmonary fibrosis significantly impacts sexual function, with 74% of patients experiencing dyspnea during sexual activity, affecting their quality of life. The study used UCSD-SOBQ and SPARC ...

Patients are usually referred for lung transplantation by a pulmonologist or primary care physician. The physical assessment and diagnostic procedures for patients with ESPD focus on the clinical ...